MELBOURNE, FL, Nov. 19, 2024 – Category V Biotech, Inc. (OTC: CATV), a leader in biotechnology innovation, announced key advancements resulting from strategic acquisitions and ongoing corporate
restructuring initiatives. The company’s recent acquisitions, combined with efforts to modernize its corporate identity, reflect its commitment to growth and operational excellence.
Strategic Acquisitions Drive Revenue Growth
In September 2024, Category V Biotech finalized the acquisition of Freddie Co, LLC and Miami FL Distribution, LLC, adding $1,000,000 in assets and establishing new revenue streams. These acquisitions
underscore the company’s focus on expanding its footprint in the biotech sector and diversifying its income sources.
The integration of these entities is already underway, and Category V Biotech anticipates the financial benefits of these acquisitions will be reflected in its year-end disclosures. While revenue from these
additions will not be fully reported until the end-of-year filings, preliminary results indicate a positive impact, setting the stage for significant contributions to the company’s financial performance moving
forward.
Proactive Debt Reduction Measures
In its ongoing commitment to protect shareholder value and enhance operational efficiency, Category V Biotech is actively working to eliminate a significant portion of its outstanding debt. By reducing
liabilities, the company aims to strengthen its financial position, provide greater stability to its shareholders, and ensure the company operates with enhanced flexibility to pursue growth initiatives.
“Our proactive approach to addressing our debt obligations reflects our unwavering commitment to fiscal responsibility and strategic growth,” said Michael Feldenkrais, CEO of Category V Biotech. “This
initiative positions us to operate more effectively, foster investor confidence, and support the long-term success of the company.”
Name Change and Corporate Rebranding
As part of its ongoing evolution, Category V Biotech has initiated steps to solidify its identity by pursuing a name change to Category V Biotech, Inc. from its former name, 4Cable TV International, Inc.. This rebranding aligns with the company’s transition to a biotechnology-focused entity, reflecting its commitment to innovation and industry leadership.
The company initially encountered delays with the FINRA name change process due to discrepancies in submitted documentation, resulting in the need to refile the application. To expedite this process and ensure compliance, Category V Biotech has engaged experienced legal counsel to assist with the name change submission and to address all outstanding requirements with FINRA. The company remains committed to completing the name and ticker symbol change in the near term and will provide regular updates to shareholders.
Looking Ahead
With the successful integration of its newly acquired entities, proactive debt reduction measures, and the ongoing name change process, Category V Biotech is well-positioned to achieve sustained growth. The leadership team remains focused on executing the company’s long-term strategy, driving operational efficiency, and delivering shareholder value.
“We are thrilled with the progress we’ve made in expanding our portfolio through the acquisitions of Freddie Co and Miami FL Distribution,” said Michael Feldenkrais, CEO of Category V Biotech. “These
acquisitions, coupled with the steps we are taking to modernize our corporate identity and eliminate debt, demonstrate our commitment to growth and innovation. We remain confident in our vision for the future of Category V Biotech and the value we will deliver to shareholders.”
About Category V Biotech, Inc.
Category V Biotech, Inc. is a biotechnology company dedicated to advancing innovative solutions that drive growth and transformation within the biotech industry. Through strategic acquisitions and
operational excellence, the company focuses on creating long-term value for shareholders while fostering advancements in health, wellness, and biotechnology.
For additional information, please contact:
Michael Feldenkrais, CEO of Category V Biotech, Inc.
Website: catvbt.com
Email: info@catvbt.com
Safe Harbor Statement
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and
uncertainties that may cause actual results to differ materially. For more details, please review the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake
any obligation to update publicly or revise any forward-looking statements, whether due to new information, future events, or otherwise.
